With 2.29 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.21 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $15.74 whereas the lowest price it dropped to was $12.61. The 52-week range on CBLL shows that it touched its highest point at $32.75 and its lowest point at $10.01 during that stretch. It currently has a 1-year price target of $33.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CBLL was down-trending over the past week, with a drop of -18.66%, but this was down by -29.91% over a month. For the next quarter, that number is -0.41. This implies an EPS growth rate of 52.00% for this year and 17.93% for next year.
Float and Shares Shorts:
At present, 35.85 million CBLL shares are outstanding with a float of 20.85 million shares on hand for trading. On 2025-03-31, short shares totaled 1.43 million, which was 399.0 higher than short shares on 1740700800. In addition to Dr. Xingjuan Chao Ph.D. as the firm’s Co-Founder, President, CEO & Director, Dr. Josef Parvizi M.D., Ph.D. serves as its Co-Founder, Chief Medical Advisor & Director.
Institutional Ownership:
Through their ownership of 0.8203 of CBLL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, CBLL reported revenue of $18534000.0 and operating income of -$12884000.0. The EBITDA in the recently reported quarter was -$10634000.0 and diluted EPS was -$0.4.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With CBLL analysts setting a high price target of 36.0 and a low target of 32.0, the average target price over the next 12 months is 33.25. Based on these targets, CBLL could surge 140.0% to reach the target high and rise by 113.33% to reach the target low. Reaching the average price target will result in a growth of 121.67% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.19728 being high and -$2.74303 being low. For CBLL, this leads to a yearly average estimate of -$2.198.
